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Abstract: Perlecan is a heparan sulfate proteoglycan protein in the extracellular matrix that structurally
and biochemically supports the cerebrovasculature by dynamically responding to changes in
cerebral blood flow. These changes in perlecan expression seem to be contradictory, ranging
from neuroprotective and angiogenic to thrombotic and linked to lipid retention. This review
investigates perlecan’s influence on risk factors such as diabetes, hypertension, and amyloid that effect
Vascular contributions to Cognitive Impairment and Dementia (VCID). VCID, a comorbidity with
diverse etiology in sporadic Alzheimer’s disease (AD), is thought to be a major factor that drives the
overall clinical burden of dementia. Accordingly, changes in perlecan expression and distribution in
response to VCID appears to be injury, risk factor, location, sex, age, and perlecan domain dependent.
While great effort has been made to understand the role of perlecan in VCID, additional studies are
needed to increase our understanding of perlecan’s role in health and in cerebrovascular disease.
Keywords: perlecan; extracellular matrix; basement membrane; VCID; vascular risk factors;
and dementia
1. Extracellular Matrix and Perlecan
The basement membrane (BM) is a thin layer of extracellular matrices (ECMs) that anchors
the epithelium (e.g., respiratory tract), mesothelium (e.g., peritoneal cavity), and endothelium (e.g.,
vasculature) to the underlying smooth muscle and connective tissue [1,2]. This specialized form of ECM
is a scaffolding of interwoven macromolecules and proteins that provide structural support, contribute to
differentiation, and serve as a signaling platform (reviewed in [3–6]). This dynamic interface represents
a delicate balance among protein synthesis, proteolysis, and metabolism [4,7–9], contributing to cellular
plasticity and tissue specificity. The vascular BM not only mediates compartmentalization but also
creates a selective barrier to infiltrating proteins and cells in parts of the body, such as the brain,
sustaining blood–brain barrier (BBB) integrity [4,7–9]. Ranging from 20 to 200 nm, the ECM consists of
over 20 proteins, including a number of glycoproteins such as laminins, collagen IV, nidogens, and
heparan sulfate proteoglycans (HSPG) (reviewed in [3–6]).
Perlecan is one of the most abundant heparan sulfate proteoglycans (HSPG) [10], encoded
by HSPG2 on chromosome 1 [11–13]. The role of perlecan has been studied in a multitude of
cellular processes ranging from cell adhesion [14,15], wound healing [16], angiogenesis [17–20],
neuroprotection [18,21], and normal development of the heart, bone, cartilage, and brain [22–27].
Perlecan consists of a core protein with a size between 467 kDa (humans) and over 750 kDa with the
addition of three to four glycosaminoglycan (GAG) side chains [28,29]. This multi-domain molecule is
composed of five distinct regions, termed domains one to five (DI–V) (reviewed in [30–32]). DI contains
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a Sperm, Enterokinase and Agrin fold with GAG and heparan sulfate (HS) attachment sites that has
been proposed to facilitate the release of heparan binding growth factors in wound healing [33–35].
This domain has a distinct, perlecan specific protein motif that does not share homology with any
other proteins [36]. Truncated perlecan DI, found in Hspg2−/− or perlecan knock out mice, has been
associated with complete loss of function, embryonic lethality (~E10–12), enlarged ventricles, smaller
brains, and weakened vasculature leading to severe bleeding and heart malformations [24,25,37].
Rescuing this phenotype via cartilage-specific perlecan (Hspg2−/−; Col2a1-Hspg2TG/−) knock in [38]
results in 50% more survivability at ~E10–12 [39], normal cephalic development [39], intact BBB [40],
but decreased neurogenesis [41], and endothelial [42] and pericyte [40] dysfunction following injury.
Interestingly, an altered attachment site of DI for HS side chains, due to the lack of exon 3 (Hspg2∆3/∆3),
did not affect perlecan expression [43], nor associated with birth defects or phenotypic developmental
abnormalities other than congenital cataracts [43]. However, vascular injury, induced by the ligation
of the distal carotid artery in the Hspg2∆3/∆3 mice has been found to contribute to an increased
intimal hyperplasia [44]. Moreover, smooth muscle cells, isolated from Hspg2∆3/∆3 have shown altered
binding of fibroblast growth factor (FGF-2) and a greater proliferation capacity when compared
with wild type [43]. DII, containing four low density lipoprotein (LDL) receptor motifs and an
immunoglobulin-like (IG) fold, is suggested to play a role in development via wingless (Wnt),
LDL, and calcium signaling [45–48], whereas DIII contains laminin epidermal growth factor (EGF)
and laminin IV type A (laminin B) domains that can directly bind fibroblast growth factor [48–50].
Perlecan-deficient endothelial cells, via antisense targeted against DIII, have been associated with
an increased thrombotic occlusion rate, possibly due to the inability to bind FGF [51]. A C1532Yneo
mutation in DIII in perlecan hypomorph (pln−/−) mice results in more than 90% reduction in perlecan
expression [52]. These mice display musculoskeletal tissue disorders, resembling the Schwartz–Jampel
syndrome (SJS) in humans [52], a disease due to HSPG2 gene mutation [53–60]. Furthermore, larger
infarcts and worse functional deficits have been reported in perlecan hypomorph mice following
middle cerebral artery occlusion (MCAo) [18,61]. The repeating Ig C2-type modules in DIV, with
or without additional GAG attachment site, determine the adhesion properties of perlecan to other
ECM proteins [47,62]. The perlecan C-terminal, termed endorepellin or DV, contains three laminin
G-like subdomains with dual EGF-like domains [36,48] and can be cleaved by proteases such as matrix
metalloproteases (MMPs) or cathepsins [18,61,63–67]. DV has been linked to anti-angiogenic activity
in tumor growth [20], pro-angiogenic and neuroprotective effects in ischemia [19] as well as to amyloid
beta (Aβ) toxicity [17,21,68]. Interestingly, the third laminin G-like subdomain (LG3) appears to be
particularly bioactive and may convey much of DV’s reported biological activity [18,20].
Overall, these observations provide strong evidence that perlecan is essential for brain, bone,
heart, and cartilage development and plays a critical role in the maintenance of homeostatic balance in
the brain following injury.
2. Perlecan and the Cerebrovasculature in Disease and Stroke
The cerebral vasculature is composed of distinct types of vessels, i.e., pial arteries, arterioles,
capillaries, or venules that are structurally and biochemically different, contributing to their specificity.
The pial arteries consist of three main layers from inside out: the tunica intima that contains both
endothelial cells and BM, surrounded by the tunica media, compromised by smooth muscle cells and
the most outer part, the tunica adventitia (or connective tissue). As these vessels dive into the brain
parenchyma and branch into smaller and smaller segments, they give rise to brain arteriole and capillary
networks, while losing their smooth muscle (SMC) coverage but gaining more pericytes and astrocytic
endfeet. All of these cells regulate and/or secrete perlecan [15,40,69–76]. Studies investigating the effects
of altered perlecan expression are contradictory, ranging from pro vs. anti-angiogenic [17,18,70,77], or
associated or not with plaque and thrombotic core proteins [78–84]. The role of perlecan may depend
on the model, size of the blood vessel, sex (female vs. male), and age.
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Cerebrovascular diseases represent one of the top five most common causes of death in the
United States [85]. As we age, our vasculature undergoes degeneration due to the accumulation of
mechanical and sheer stress induced by innate fluctuations in blood pressure [86]. Arteriolosclerosis,
arterial stiffness, and reduced compliance, are among the first pathologies to present, leading to altered
cerebrovascular blood flow (CBF) and ECM protein metabolism, or the remodeling of ECM. Moreover,
proteases known to cleave perlecan such as matrix MMPs or cathepsins [18,61,63–67] increase in
cerebrovascular diseases (reviewed in [87]). Fluctuation of perlecan expression has been reported in
aging; perlecan levels in mouse brain were high at 3 months, decreased at 8 months, followed by a
secondary increase at 16 months of age [88]. However, a study by Kerever et al. reported no change in
perlecan expression in the subventricular zone of aged mice without comorbidity [89]. Age-related
structural changes are associated with decreased CBF, contributing to cell senescence, damage, and
dementia [90–98]. A term that encompasses cognitive decline associated with vascular change is
Vascular contributions to Cognitive Impairment and Dementia or VCID. VCID is the second leading
cause of dementia [99–101] behind Alzheimer’s disease (AD) [102–105] with many of the same vascular
risk factors, such as, age, sex, hypertension [106], atherosclerosis, and diabetes mellitus (DM) [107–114].
How metabolic changes such as high glucose, high insulin, or high free fatty acid levels individually or
in combination affect perlecan distribution and expression is reviewed in Table 1. VCID etiology ranges
from cerebrovascular disruption, seen in small vessel diseases of the brain, including arteriolosclerosis,
and cerebral amyloid angiopathy (CAA, pathologic accumulation of amyloid beta (Aβ) protein in
brain blood vessels), to the profound symptomatic damage following acute stroke. These vascular
risk factors may increase BM thickness contributing to the narrowing of vascular lumen and to the
disruption of BBB integrity. Changes in the BBB are dynamic, as it opens and closes multiple times
within the first hours to days after ischemic injury [115]. This disrupted BBB provides a pathway
for inflammatory cells that may infiltrate the brain and release additional proteases, free radicals,
chemokines, and cytokines [116–118]; further contributing to altered ECM synthesis of matrix proteins
or proteolysis, splice variants, smooth muscle cell migration and proliferation [119]. The extent of the
injury and remodeling in the ECM is determined by the vascular injury, loss of blood flow, resultant
inflammation, and ultimately the changes in oxygen and nutrient supply to the neurons and their
support cells (glia and immune cells).
Table 1. Metabolic Changes and Perlecan.




























[C57BL/6 mice], 6–8 wk Kidney Male
↓ perlecan core protein, no
change in mRNA stability
in DN vs. control
[122]
STZ [SD rats], 5 and 12
mo Kidney Male
− (no change) in perlecan
(DI, clone16) [123]
STZ [C57Bl/6 mice], 6 mo Liver Male ↓ perlecan [124]
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Kidney Male(mice)
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A7L6) [126]
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↑ perlecan following IL-1β
treatment
↑ HS chains by TNF
[131]
Wound healing [Retired




↑ perlecan (DI, clone










↑ TGF, advanced glycation,
and high glucose [132]
High glucose [Human] Trophoblast cellline 3A-Sub-E n. sp.
↓ perlecan (DIV, clone
A7L6) [133]
[Human] gestational age
5–7wk, 15–26 wk, 36–40
wk
Placenta n. sp.
↓ (DIV, clone A7L6) during
placental maturation in
normal pregnancies
↑ in gestational diabetes
[134]
Abbreviations. ↑: increase; ↓: decrease; −: no change; ACLT: anterior cruciate ligament transection; BTBR ob/ob:
black and tan, brachyuric, obese (leptin-deficiency); DI: domainI; DIV: domain IV; db: diabetic (leptin defiency); DN:
diabetic nephropathy; HS: Heparan sulphate; HSPG2: Heparan sulphate proteoglycan 2; IDDM: insulin-dependent
diabetes mellitus; mo: month; NIDDM: non-insulin-dependent diabetes mellitus; n. sp.: not specified; SD:
Sprague–Dawley; STZ: streptozotocin; TGF: transforming growth factor; TNF: tumor necrosis factor; wk: week;
WKY: Wistar Kyoto; yr: year.
Atherosclerosis, a common cause and comorbidity in stroke and vascular dementia, has been linked
with the distribution of ECM proteins (e.g., perlecan) in the walls of peripheral arteries. Atherosclerosis,
a disease of large and medium sized arteries, develops in stages, starting with intimal hyperplasia due
to lipid accumulation, followed by development of plaques and thrombosis leading to vessel occlusion
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(ischemic stroke) or rupture (hemorrhagic stroke) [135–138]. Perlecan has been linked to lipid retention
in the vasculature [83], possibly through the LDL receptor motifs region in DII (additional studies on
perlecan and atherosclerotic plaques are outlined in Table 2). Increased BM perlecan expression has
been correlated with atherosclerotic lesions in experimental mice [79,81], non-human primates [139],
and in humans [80]. Interestingly, perlecan expression was found to be increased in aged human
cerebral arteries but decreased as the lesion progressed [140]. Haung et al. have shown that perlecan
accumulation via angII-driven mechanisms preceded the progression of atherosclerosis [81]. This
suggests that perlecan accumulation may increase endothelial barrier disruption resulting in lesion
formation via increased deposition of LDL. Moreover, the loss of perlecan has been associated with
less atherosclerosis in early lesions of mice without effect on the lipoprotein profile [83,141].
Table 2. Atherosclerosis and Perlecan.






ApoE and LDLR KOs
[mice] Aorta Mixed
↑ perlecan in intima and
smooth muscle cells [79]
[Human] Aorta Male
↑ perlecan (DIV, clone




LDLR−/− [mice] Aorta Female ↑ perlecan with lesion [81]





↑ perlecan with Western
diet in biglycan deficient
mice not WT





[mice], 15 and 33 wk
Aorta Mixed
↓ perlecan (core protein,
R14) at 15 and 33 wk with
smaller lesion
− No change in perlecan
mRNA
[83]




12, 20 and 24 wk
Aorta Mixed
− No change in lipid
profile upon perlecan
deletion
↓ atherosclerosis in young
heterozygous KO/apoE0















Abbreviations. ↑: increase; ↓: decrease; −: no change; AngII: Angiotensin II; ApoE: apolipoprotein E; ApoE0: apoE
gene knockout; AT1a: angiotensin II subtype-1a; DIV: domain IV; Hspg2∆3/∆3: Heparan sulphate proteoglycan 2
with deleted exon 3; KO: knock out; LDLR: low density lipoprotein receptor; wk: week; WT: wild type; yr: year.
Also, decreased heparan sulfate and perlecan levels were detected in fully developed atherosclerotic
lesions of tunica intima, derived from non-diabetic and Type 2 non-insulin-dependent diabetes mellitus
patients [142], as well as from those with carotid stenosis [143], respectively. Hence, it is plausible
that the distribution of various ECM components, especially perlecan, drives the initiation and
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progression of atherosclerosis. In contrast, an earlier study by Hollmann et al. reported decreased
perlecan expression, associated with advancing age and severity of atherosclerosis, in both normal and
atherosclerotic regions of human aorta [80]. The difference between this study and others may lie in the
method of tissue preparation and perlecan detection. Additional contradictory studies show perlecan
preventing atherosclerosis [84,144,145]. In an in vitro model, increased endothelial cell HSPG/perlecan
production led to a reduction of the atherosclerotic lesions [146].
Amyloid that accumulates within the vasculature, CAA, and brain parenchyma, forms plaques
(AD) that disrupt the distribution of perlecan (Table 3) [147–149], decreases the ability of SMC to bind
perlecan [150], and contributes to vascular wall weakening [147]. Modifications to the sulfate content of
the specific GAG chains of perlecan were also found to be critical to the binding of amyloid [151]. In a
systematic family-base genome-wide association and meta-analysis that included 15 million imputed
variants from 3524 European subjects, HSPG variant rs2445130-A (p = 8 × 10−7) had an increased
association of AD status and onset age [152]. Furthermore, HSPGs have been found in amyloid
deposits in congophilic angiopathy as well as in neuritic plaques [153]. Similarly, Lepelletier et al.
reported an association in amyloid regions with high perlecan in patients with a Braak stage >2 [154]
when using antibodies targeting DIV. However, a study by Verbeek et al. found agrin, and a lesser
extent glypican and syndecan, to be the major HSPGs associated with amyloid, whereas perlecan
was not found in hippocampal nor neocortical plaques when using antibodies against DI-DII and
DIV [155]. The lack of perlecan staining on amyloid positive vessels of CAA patients has been reported
as well [156]. These observations suggest the possibility that the pathologic absence of perlecan/DV
contributes to, and/or is the result of cerebrovascular Aβ accumulation. Functionally, treatment with a
recombinant DV of perlecan has been demonstrated to block the deleterious effects of amyloid on brain
endothelial cells [17] via α5β1 integrin receptor, a key angiogenesis receptor, downregulated after
brain development, and only to be upregulated in response to ischemic brain injury [157]. The role
of perlecan in amyloid accumulation and clearance may be intricately regulated by cell types, vary
among species, and perlecan domain dependent.
Table 3. Amyloid and Perlecan.















↑ in perlecan (DIV, 2501) in
brain regions that have ↑












Perlecan (DIV, MAB 1948)
and DI-DIIa, MAB95J10)
not associated with senile
plaques and tangles
[155]
LDLR and apoE mice Proximal aortictissue Mixed





TRE4, and C57Bl/6, 16
mo, [mice]
Capillaries Male − (no change) in perlecan [158]
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FBD CAA and plaques
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− No association perlecan
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↑ in perlecan (DIV, 1948)
associated amyloid [166]
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A/J mice Liver Mixed ↓perlecan associate with ↓amyloid [167]
[human] Cerebellum andcerebrum Mixed
↓ perlecan (DI and DII,










↓ perlecan (DI and DII,
95J10, and DIV, 1948) in
CAA and in senile plaques
[156]
Abbreviations. ↑: increase; ↓: decrease; −: no change; AD: Alzheimer’s Disease; Aβ: amyloid beta; A/J: Apoa2C
allele; APP: amyloid precursor protein (swe: Swedish mutation); PS1: presenilin1 (dE9 mutation); CAA: cerebral
amyloid accumulation, CCI: control cortical impact, DAT: dementia of the Alzheimer type; DI; domain I; DII:
domain II; DIV: domain IV; DV: domain V; FBD: familial British dementia; FDD: familial Danish dementia; HSPG2:
Heparan sulphate proteoglycan 2; LDLR: low density lipoprotein receptor; mo: month; n. sp.: not specified; SAMP8:
senescence accelerated mouse 8; LOAD: late onset Alzheimer’s Disease; LPS: lipopolysaccharide; TBI: traumatic
brain injury; WB: western blot; wk: week; yr: year.
Stroke results from the disruption of blood flow to the brain due to the narrowing or occlusion of a
vessel (ischemic) or to the weakening of the vessel wall (hemorrhagic). Perlecan was found to be lower
in non-human primate models of focal cerebral ischemia [63,169], whereas DV has been demonstrated
to increase in rodent models of stroke (endothelin-1 and tandem common carotid artery occlusion
and distal middle cerebral artery occlusion) [18]. The therapeutic potential of recombinant DV after
ischemic stroke has been demonstrated by us and others [18,40]. Correspondingly, the lack of perlecan,
when using hypomorphs, Col2a1-Hspg2TG/− and Hspg2−/− mice, was associated with larger infarcts
as well as worse functional outcomes after MCAo and decreased neurogenesis, respectively [18,40].
Increased perlecan expression was found following traumatic brain injury in mice [75] as well as in
human samples from patients with brain arteriovenous malformation [170]. Similarly, Nugent el al.
showed increased thrombotic occlusion rates in perlecan-deficient endothelial cells in a porcine carotid
artery injury model [51], not surprisingly as perlecan antithrombotic/anticoagulant studies have shown
perlecan directly binding to anti-thrombin III [171].
Hypertension is an important risk factor for stroke and vascular dementia and can occur at any
age as well as in pregnancy. Vascular remodeling of peripheral and cerebral blood vessels is a common
feature of hypertension that has been linked to changes in perlecan (Table 4). Various studies have
shown that increased expression and accumulation of collagen IV and elastin in peripheral and cerebral
arteries lead to arterial stiffness. However, only a small number of investigators have studied the
expression of perlecan in various models of hypertension. McGuire and colleagues were the first
to report increased expression of perlecan in the aorta of spontaneously hypertensive rats (SHR), a
model of essential hypertension [172]. This finding was corroborated in the aorta of hypertensive rats,
induced by high salt diet [173]. Nonaka et al. reported reduced endothelium-dependent relaxation
through lower endothelial nitric oxide synthase (eNOS) expression in aortas of perlecan-deficient mice
and when perlecan is knocked-down in human aortic endothelial cells [42], suggesting that perlecan
may play a role in vasodilation. Furthermore, angII and Western diet have been reported to increase
level of perlecan in biglycan deficient mice [82]. Haung et al. [81] showed that perlecan accumulation,
via angII-mediated mechanisms, precedes the progression of atherosclerosis, suggesting that perlecan
accumulation may facilitate endothelial barrier disruption, resulting in an increased deposition of
LDL, the hallmark of atherosclerotic lesion formation. However, no change was detected in perlecan
expression in a coarctation of abdominal aorta model of hypertension in rats [174]. In pregnant
women, an association was found between increased plasma concentration of perlecan and early onset
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of gestational hypertension [175]. The authors attributed their findings to impaired microvascular
perfusion leading to the degradation of glycocalyx of the kidneys. Likewise, early preeclampsia with or
without HELLP (hemolysis, elevated liver enzymes, and a low platelet count) syndrome was associated
with an increased placental perlecan expression that showed a positive correlation with maternal
vascular malperfusion [176]. In contrast, the findings by Guo et al. showed decreased perlecan
concentration in urine when compared the gestational hypertension group with controls, indicating
glomerular filtration barrier injury and renal dysfunction [177]. Collectively, these observations paint a
complex and underexplored role for perlecan in hypertension in the cerebrovasculature and beyond.
Table 4. Hypertension and Perlecan.
Model [Organism] Tissue/Sample Sex Findings Reference
Preeclampsia [Human] Urine Female ↓ perlecan compared tonormotensive controls [177]
SHRSP [Rat] Aorta Male ↑ perlecan [172]
Coarciation






↓ perlecan (MP4) during
placental maturation
↑ perlecan in early
pregnancy loss and in
preeclampsia without
HELLP
↓ perlecan in late
preeclampsia
[176]
Abbreviations. ↑: increase; ↓: decrease; −: no change; HELLP: hemolysis, elevated liver enzymes, and a low platelet
count; n. sp.: not specified; SHRSP: spontaneously hypertensive stroke prone rats; wk: week.
3. Conclusions
Besides aging, atherosclerosis, hypertension, and diabetes are cerebrovascular risk factors for VCID,
dementia and stroke, making it difficult to tease out the underlying mechanisms of cognitive decline.
In addition, changes in perlecan expression and distribution in response to VCID appears to be injury,
risk factor, location, sex, age, and perlecan domain dependent. Overall, great effort has been made in
recent decades in understanding the role of perlecan in VCID. While recombinant perlecan DV, in mice
and rats, has been found to be angiogenic, neuroprotective, and neuroreparative [17–19,68,157,178–180],
new studies are warranted to address the role of perlecan and its domains in health and in combination
with cerebrovascular risk factors.
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